Insight

Elizabeth Smyth: Review on a Key Emerging Biomarker in Gastric and Gastroesophageal Cancer

Elizabeth Smyth/X

Aug 2, 2025, 00:36

Elizabeth Smyth: Review on a Key Emerging Biomarker in Gastric and Gastroesophageal Cancer

Elizabeth Smyth, Clinical Lead at the Oxford Clinical Trials Office, shared a post on X:

“Very pleased to share this review on FGFR2b which is a key emerging biomarker in gastric and gastroesophageal cancer.

Looking forward to seeing those FORTITUDE 101 results soon!

Hopefully ESMO25 in Berlin!

Thanks to all my co-authors! ”

Elizabeth Smyth

Title: FGFR2b protein overexpression: An emerging biomarker in vgastric and gastroesophageal junction adenocarcinoma

Journal: Cancer Treatment Reviews

Authors: Elizabeth C. Smyth, Kyoung-Mee Kim, Sun Young Rha, Zev A. Wainberg, Hayden Honeycutt, Erica Sommermann, Atsushi Ochiai

Read the full article.

Elizabeth Smyth

More posts featuring Elizabeth Smyth on OncoDaily.

Atsushi Ochiai cancer Elizabeth C. Smyth Elizabeth Smyth Erica Sommermann ESMO25 FGFR2b FORTITUDE-101 gastric adenocarcinoma gastric cancer gastroesophageal cancer Gastroesophageal Junction Adenocarcinoma Hayden Honeycutt Kyoung-Mee Kim Lizzy Smyth OncoDaily Oncology Sun Young Rha Zev A. Wainberg

FDA Priority Review Granted for TAR-200 After 82% Complete Response in BCG-Unresponsive Bladder Cancer

Paolo Tarantino: AACR Journals' Power Move for Reviewers

Best Immunotherapy Highlights from ESMO TAT ASIA 2025 You Shouldn't Miss

Oncologist Near Me – Nagashree Seetharamu: A Journey of Healing, Mentorship, and Leadership

Mohit Manrao: FDA Grants Priority Review for sBLA in Resectable Early-Stage Gastric and GEJ Cancers